Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Aug;33(8):4871-4877.
doi: 10.1007/s10787-025-01876-x. Epub 2025 Jul 29.

Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow  1   2   3 , Dinesh Sangarran Ramachandram  4 , Syed Shahzad Hasan  1 , Kaeshaelya Thiruchelvam  5
Affiliations
Meta-Analysis

Effect of N-Acetylcysteine on mortality in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials

Chia Siang Kow et al. Inflammopharmacology. 2025 Aug.

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has prompted global interest in potential adjunctive therapies. N-acetylcysteine (NAC), a mucolytic agent that enhances intracellular glutathione synthesis, has antioxidant properties and may indirectly modulate inflammation through redox regulation. While preclinical and observational data suggest potential mortality benefits, findings from randomized controlled trials (RCTs) have been inconsistent.

Objective: To systematically review and synthesize the evidence from RCTs evaluating the effect of NAC on mortality in patients with COVID-19.

Methods: This systematic review and meta-analysis was conducted according to PRISMA guidelines. Six databases were searched from inception to March 21, 2025. Eligible studies were RCTs comparing NAC to placebo or standard care in adult COVID-19 patients, with mortality as a reported outcome. Two reviewers independently screened studies, extracted data, and assessed risk of bias using the Cochrane RoB 2 tool. Statistical analyses were performed with a random-effects model to estimate pooled odds ratios (ORs) and 95% confidence intervals (CIs).

Results: Ten RCTs comprising 1,424 patients were included. NAC regimens varied by dose and route. The pooled OR for mortality was 0.49 (95% CI: 0.25-0.94; I2 = 67%), indicating a 51% reduction in the odds of death among patients receiving NAC. Seven studies had low risk of bias; three had some concerns, primarily due to open-label designs.

Conclusion: NAC may reduce mortality in COVID-19 patients, particularly when administered at higher doses or via non-oral routes. Further large-scale RCTs are needed to confirm these findings and establish optimal dosing and administration strategies.

Keywords: COVID-19; Death; N-Acetylcysteine; NAC; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interests: The authors have no relevant financial or non-financial interests to disclose.

References

    1. Abbasi S, Fani M, Sayar S, Radmanesh E, Jelvay S, Pahlavanzadeh B et al (2023) The effects of vitamin D3 and N-acetylcysteine administration in patients with COVID-19 hospitalization in the Iranian population. Int J Med Lab 10:217–228
    1. Atefi N, Goodarzi A, Riahi T et al (2023) Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: a randomized controlled clinical trial. Immun Inflamm Dis 11(11):e1083. https://doi.org/10.1002/iid3.1083 - DOI - PubMed - PMC
    1. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) N-acetylcysteine—a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7(4):355–359. https://doi.org/10.1016/j.coph.2007.04.005 - DOI - PubMed - PMC
    1. Chen CH, Hung KF, Huang CY, Leong JL, Chu YC, Chang CY, Wang ML, Chiou SH, Cheng YF (2023) Is N-acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis. J Chin Med Assoc 86(3):274–281 - PubMed
    1. Cochrane Methods Bias. (2023). RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-...

MeSH terms

LinkOut - more resources